|
MechanismProton pump inhibitors |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase 1 Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus
Secretrol administered over a 6 month period to patients with Barrett's Esophagus will be safe and well tolerated. Further, pH control will be evaluated in the distal esophageal mucosa and just below the squamocolumnar junction.
Phase 1 Study of Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)
Evaluate the safety of Secretrol® in patients undergoing endoscopic mucosal resection for early adenocarcinoma of the esophagus.
/ Unknown statusPhase 1/2 Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in Gastroesophageal Reflux Disease(GERD)Patients With Severe Erosive Esophagitis(EE).
To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with Secretol 80/80 versus Nexium 40 mg daily.
100 Clinical Results associated with Effexus Pharmaceutical LLC
0 Patents (Medical) associated with Effexus Pharmaceutical LLC
100 Deals associated with Effexus Pharmaceutical LLC
100 Translational Medicine associated with Effexus Pharmaceutical LLC